AcelRx Pharmaceuticals plans public sale of 10 million common shares

Public offering conducted by Jefferies, Cowen and Canaccord Genuity

By Devika Patel

Knoxville, Tenn., Dec. 5 - AcelRx Pharmaceuticals, Inc. said it will sell 10 million common shares in a public offering with a greenshoe of 1.5 million additional shares.

Jefferies & Co., Inc. and Cowen and Co., LLC are the joint bookrunners. Canaccord Genuity Inc. is a co-lead manager.

Based in Redwood City, Calif., AcelRx is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.